These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32728158)

  • 1. Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease.
    Simard JC; Thibodeau JF; Leduc M; Tremblay M; Laverdure A; Sarra-Bournet F; Gagnon W; Ouboudinar J; Gervais L; Felton A; Letourneau S; Geerts L; Cloutier MP; Hince K; Corpuz R; Blais A; Quintela VM; Duceppe JS; Abbott SD; Blais A; Zacharie B; Laurin P; Laplante SR; Kennedy CRJ; Hébert RL; Leblond FA; Grouix B; Gagnon L
    Sci Rep; 2020 Jul; 10(1):12778. PubMed ID: 32728158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84.
    Gagnon L; Leduc M; Thibodeau JF; Zhang MZ; Grouix B; Sarra-Bournet F; Gagnon W; Hince K; Tremblay M; Geerts L; Kennedy CRJ; Hébert RL; Gutsol A; Holterman CE; Kamto E; Gervais L; Ouboudinar J; Richard J; Felton A; Laverdure A; Simard JC; Létourneau S; Cloutier MP; Leblond FA; Abbott SD; Penney C; Duceppe JS; Zacharie B; Dupuis J; Calderone A; Nguyen QT; Harris RC; Laurin P
    Am J Pathol; 2018 May; 188(5):1132-1148. PubMed ID: 29454750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice.
    Lu H; Yuan X; Zhang Y; Han M; Liu S; Han K; Liang P; Cheng J
    Biomed Pharmacother; 2020 Sep; 129():110347. PubMed ID: 32535386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 9-Cyclopropylethynyl-2-((
    Labéguère F; Dupont S; Alvey L; Soulas F; Newsome G; Tirera A; Quenehen V; Mai TTT; Deprez P; Blanqué R; Oste L; Le Tallec S; De Vos S; Hagers A; Vandevelde A; Nelles L; Vandervoort N; Conrath K; Christophe T; van der Aar E; Wakselman E; Merciris D; Cottereaux C; da Costa C; Saniere L; Clement-Lacroix P; Jenkins L; Milligan G; Fletcher S; Brys R; Gosmini R
    J Med Chem; 2020 Nov; 63(22):13526-13545. PubMed ID: 32902984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
    Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
    J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the G-Protein-Coupled Receptor 84 (GPR84) by Agonists and Antagonists.
    Chen LH; Zhang Q; Xie X; Nan FJ
    J Med Chem; 2020 Dec; 63(24):15399-15409. PubMed ID: 33267584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight.
    Ookawara M; Matsuda K; Watanabe M; Moritoh Y
    J Pharmacol Exp Ther; 2020 Oct; 375(1):21-27. PubMed ID: 32719069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medium-chain fatty acids suppress lipotoxicity-induced hepatic fibrosis via the immunomodulating receptor GPR84.
    Ohue-Kitano R; Nonaka H; Nishida A; Masujima Y; Takahashi D; Ikeda T; Uwamizu A; Tanaka M; Kohjima M; Igarashi M; Katoh H; Tanaka T; Inoue A; Suganami T; Hase K; Ogawa Y; Aoki J; Kimura I
    JCI Insight; 2023 Jan; 8(2):. PubMed ID: 36480287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders.
    Chen Z; Wang GX; Ma SL; Jung DY; Ha H; Altamimi T; Zhao XY; Guo L; Zhang P; Hu CR; Cheng JX; Lopaschuk GD; Kim JK; Lin JD
    Mol Metab; 2017 Aug; 6(8):863-872. PubMed ID: 28752050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of GPR84 deletion on obesity and diabetes development in mice fed long chain or medium chain fatty acid rich diets.
    Du Toit E; Browne L; Irving-Rodgers H; Massa HM; Fozzard N; Jennings MP; Peak IR
    Eur J Nutr; 2018 Aug; 57(5):1737-1746. PubMed ID: 28429080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
    Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-substituted phenylbenzamides of the niclosamide chemotype attenuate obesity related changes in high fat diet fed mice.
    Bhagat HA; Compton SA; Musso DL; Laudeman CP; Jackson KMP; Yi NY; Nierobisz LS; Forsberg L; Brenman JE; Sexton JZ
    PLoS One; 2018; 13(10):e0204605. PubMed ID: 30359371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure.
    Nguyen QT; Nsaibia MJ; Sirois MG; Calderone A; Tardif JC; Fen Shi Y; Ruiz M; Daneault C; Gagnon L; Grouix B; Laurin P; Dupuis J
    Cardiovasc Res; 2020 Jan; 116(1):171-182. PubMed ID: 30753422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits.
    Lee K; Haddad A; Osme A; Kim C; Borzou A; Ilchenko S; Allende D; Dasarathy S; McCullough A; Sadygov RG; Kasumov T
    Mol Cell Proteomics; 2018 Dec; 17(12):2371-2386. PubMed ID: 30171159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD.
    Gehrke N; Biedenbach J; Huber Y; Straub BK; Galle PR; Simon P; Schattenberg JM
    Sci Rep; 2019 Mar; 9(1):4007. PubMed ID: 30850619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly identified peptide hormone inhibits intestinal fat absorption and improves NAFLD through its receptor GPRC6A.
    Teng B; Huang C; Cheng CL; Udduttula A; Yu XF; Liu C; Li J; Yao ZY; Long J; Miao LF; Zou C; Chu J; Zhang JV; Ren PG
    J Hepatol; 2020 Aug; 73(2):383-393. PubMed ID: 32147363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
    Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
    Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palmitoleic Acid Decreases Non-alcoholic Hepatic Steatosis and Increases Lipogenesis and Fatty Acid Oxidation in Adipose Tissue From Obese Mice.
    Cruz MM; Simão JJ; de Sá RDCC; Farias TSM; da Silva VS; Abdala F; Antraco VJ; Armelin-Correa L; Alonso-Vale MIC
    Front Endocrinol (Lausanne); 2020; 11():537061. PubMed ID: 33117273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development.
    Yang M; Liu Q; Huang T; Tan W; Qu L; Chen T; Pan H; Chen L; Liu J; Wong CW; Lu WW; Guan M
    Theranostics; 2020; 10(24):10874-10891. PubMed ID: 33042259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.